A Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea

Phase 1

Completed

• Conditions: Rhinoconjunctivitis
• Interventions: Biological: Allergovac depot with Olea europaea pollen extract

• Registration Number: NCT02849210
• Lead Sponsor: Roxall Medicina España S.A

Brief Summary

The study was designed according to the draft of allergenic product regulation published by Spanish Regulatory Agency. The aim of the study is to evaluate the safety and tolerability of subcutaneous immunotherapy with Olea europaea pollen extract in patients with rhinoconjunctivitis with or without associated mild asthma. In addition, surrogate efficacy parameters will be evaluated: immunoglobulin level changes and skin reactivity

Detailed Description

An study conducted througout Spain with 4000 allergic patients (Alergoloógica 2005) showed that 47% of patients with rhinoconjuncitivits and 51% of asthmatic patients were sentitized to olive pollen. This gives us an idea of the importance of this allergen sensitization in Spain.

Study Timeline

• Study Start: 2015-09
• Study First Submitted: 2016-07-22
• Study First Submitted QC: 2016-07-26
• Study First Posted: 2016-07-29
• Primary Completion: 2017-06-02
• Study Completion: 2017-06-02
• Status Verified: 2017-10
• Last Update Submitted: 2017-10-20
• Last Update Posted: 2017-10-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 47

Inclusion Criteria

1. Patients must sign the informed consent form.
2. Patients must be between 18 and 60 years of age.
3. Patients with seasonal allergic rhinoconjunctivitis against Olea europea during a minimum of 2 years prior to study participation. Although allergic rhinoconjunctivitis is the pathology under study, the inclusion of patients with mild concomitant asthma is allowed.
4. Patients who obtained a prick test result ≥ 3 mm diameter to Olea europaea Positive and negative control of the test should give consistent results.
5. Patients with specific immunoglobulin E ≥ class 2 (CAP/PHADIA) to Olea europaea.
6. Patients sensitized to Olea europaea with clinically relevant symptoms in which treatment with Olea europea 100% vaccine is indicated.
7. Patients who met all windows of treatment described in the protocol for both, treatment and study procedures.
8. Women of childbearing potential must have a negative urine pregnancy test at Screening visit/Visit 0.
9. Women of childbearing potential must agree to use an appropriate contraception method during the study if they are sexually active.

Exclusion Criteria

1. Patients who received immunotherapy in the previous 5 years for Olea europaea or for any allergen with cross reactivity or patients that are currently receiving immunotherapy for any allergen.
2. Patients with severe asthma or forzed expiratoy volumen in 1 second FEV1< 70% even if the are pharmacologically controlled .
3. Patients with: immunological, cardiac, renal or hepatic illnesses or any other medical condition that the investigator deems relevant so as to interfere with the study.
4. Polisensitized patients to other inhalant allergens besides Olea europaea, if in the judgment of the investigator may present symptoms clinically relevant to those other airborne allergens while participating in this study
5. Patients with a previous history of anaphylaxis
6. Patients with chronic urticaria,
7. Patients with moderate to severe atopic dermatitis
8. Patients who have participated in another clinical trial within 3 month prior to enrolment.
9. Patients under treatment with tricyclic antidepressives, phenothiazines , β-blockers, or Angiotensin Converting Enzyme Inhibitors (ACEI)
10. Female patients who are pregnant or breast-feeding
11. Patient who does not attend the visits
12. Patient's lack of collaboration or refusal to participate.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Allergovac depot	Allergovac depot with Olea europaea pollen extract	Allergovac depot with Olea europaea pollen extract

Primary Outcome Measures

Name	Time	Method
Number and severity of adverse reactions as a measure of Safety and tolerability	17 weeks treatment period

Secondary Outcome Measures

Name	Time	Method
Immunoglobulin changes from baseline	At baseline and 1 week after last administered dose
Cutaneous reactivity changes from baseline	At baseline and 1 week after last administered dose	Skin prick test will be conducted at baseline and 1 week after last administered dose to measure the wheal área changes in mm2

Trial Locations

Locations (5)

Hospital Santa Bárbara; 🇪🇸 Puertollano, Ciudad Real, Spain

Complejo Hospitalario de Jaén; 🇪🇸 Jaén, Andalucía, Spain

Hospital Infanta Cristina; 🇪🇸 Badajoz, Spain

Hospital Costa de la Luz; 🇪🇸 Huelva, Spain

Hospital Nisar Sevilla; 🇪🇸 Sevilla, Spain